Frank John Podlaski

Title: Frank John Podlaski: Innovator in Cytokine Research

Introduction

Frank John Podlaski is a notable inventor based in New City, NY (US). He has made significant contributions to the field of immunology, particularly in the development of cytokine proteins. With a total of three patents to his name, Podlaski's work has advanced our understanding of immune responses.

Latest Patents

Among his latest patents is the purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto. This invention introduces a novel cytokine protein known as IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF). It is produced and synthesized by human NC-37 B lymphoblastoid cells. CLMF synergistically enhances the cytolytic activity of Lymphokine Activated Killer (LAK) cells when combined with low concentrations of IL-2. Additionally, CLMF is capable of stimulating T-cell growth. The patent also claims the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells, and antibodies to CLMF.

Career Highlights

Frank John Podlaski is currently associated with Hoffmann-La Roche Inc., where he continues to contribute to innovative research in biotechnology. His work has been pivotal in advancing therapeutic approaches in immunology.

Collaborations

Throughout his career, Podlaski has collaborated with esteemed colleagues such as Maurice Kent Gately and Ulrich Andreas Gubler. These collaborations have further enriched his research and development efforts.

Conclusion

Frank John Podlaski's contributions to cytokine research and his innovative patents have made a significant impact in the field of immunology. His work continues to inspire advancements in therapeutic applications.